Persistent Gynecomastia due to Short-term Low-dose Finasteride for Androgenetic Alopecia

• Published in: JCEM case reports Vol. 2; no. 5; p. luae050
• Main Authors: Farkas, Hal Steven, Jee, Youn Hee, Szymczuk, Vivian, Leschek, Ellen Werber
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.05.2024
• Subjects: Patient; finasteride; gynecomastia; androgenetic alopecia
• ISSN: 2755-1520; 2755-1520
• DOI: 10.1210/jcemcr/luae050

We report a case of persistent gynecomastia in a healthy 20-year-old man after 1 month of low-dose finasteride. Finasteride was discontinued after 2 months, and gynecomastia was unchanged 5 months after drug withdrawal. The gynecomastia regressed but did not resolve after 6 months of treatment with raloxifene, a selective estrogen receptor modulator. One year later, bilateral mammoplasty was performed to remove the remaining breast tissue. Finasteride, a 5-alpha-reductase inhibitor, is widely used for the treatment of androgenetic alopecia. Gynecomastia is an expected side effect of this therapy given its mechanism of action. However, only 8 cases of gynecomastia have been reported with low-dose (1 mg daily) finasteride treatment since its approval for androgenetic alopecia in 1997. This raises the concern that gynecomastia resulting from low-dose finasteride is significantly underreported, causing inadequately informed patients. Further, because of the risk of gynecomastia, it is important for prescribing physicians to counsel patients regarding this complication and to consider early intervention when finasteride-induced gynecomastia first arises to prevent fibrosis and thus irreversible gynecomastia.